TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9692448

Group type: EXPERIMENTAL
Intervention: 1 g of L-arginine administered during the first 30 minutes of cardioplegic arrest
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no L-arginine supplementation)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: L-arginine group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: L-arginine group and control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cold cardioplegia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Warm cardioplegia
Number of subjects: 50
Study: 8747049

Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 232

Group type: COMPARATOR
Intervention: SUZI
Number of subjects: 232

Group type: COMPARATOR
Intervention: Both SUZI and ICSI
Number of subjects: 232
Study: 2193493

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 20218011

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule formulations of digoxin (0.4 mg) with in vitro burst times of 2.9 and 16 min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule formulations of digoxin (0.4 mg) with in vitro burst times of 62 and 229 min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: In vitro burst time
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mean time to peak plasma level
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All capsule formulations
Number of subjects: 16
Study: 28956942

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Workplace Dialogue Intervention (WDI)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Combination of ACT and WDI
Number of subjects: 352

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 352
Study: 28300529

Group type: EXPERIMENTAL
Intervention: PCV7 vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV10 vaccination
Number of subjects: 0
Study: 25808074

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (15, 20, or 30 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 32
Study: 26162817

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 83
Study: 24622525

Group type: EXPERIMENTAL
Intervention: RN-SBIRT training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-directed Web site on alcohol-related care
Number of subjects: 0
Study: 21055743

Group type: EXPERIMENTAL
Intervention: Sitting with closely approximated legs
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sitting with closely approximated legs with a lap pad
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sitting with legs apart at a 70° angle with a lap pad
Number of subjects: 29
Study: 19055224

Group type: EXPERIMENTAL
Intervention: Marginal periosteal pedicle graft (MPP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open flap debridement
Number of subjects: 15
Study: 16549967

Group type: EXPERIMENTAL
Intervention: Structured intermittent HAART (4 weeks on/8 weeks off), n = 23
Number of subjects: 46

Group type: COMPARATOR
Intervention: Continuous HAART
Number of subjects: 46
Study: 12729123

Group type: EXPERIMENTAL
Intervention: Three Ullevaal hip screws
Number of subjects: 278

Group type: COMPARATOR
Intervention: Two Hansson hook-pins
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Peroperative drill penetration of the femoral head
Number of subjects: 278
Study: 10750670

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 100)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (n = 101)
Number of subjects: 201
Study: 9623429

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 84

Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 84
Study: 7837074

Group type: EXPERIMENTAL
Intervention: 3.5 mm sutureless incisions
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5.1 mm sutureless incisions
Number of subjects: 80
Study: 2980629

Group type: EXPERIMENTAL
Intervention: Admission to a nursing unit where nursing was perceived as the chief therapeutic activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal patient pathway (control group)
Number of subjects: 0
Study: 29468446

Group type: EXPERIMENTAL
Intervention: Long-term temozolomide therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (short-term temozolomide)
Number of subjects: 0
Study: 28174170

Group type: EXPERIMENTAL
Intervention: AF‐Defrag group (n=29)
Number of subjects: 137

Group type: COMPARATOR
Intervention: CPVI+Line group (n=54)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: CPVI+Line+CFAE group (n=54)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: CPVI+Line+CFAE group
Number of subjects: 137

Group type: COMPARATOR
Intervention: CPVI+Line group
Number of subjects: 137

Group type: COMPARATOR
Intervention: CPVI+Line+CFAE group and CPVI+Line group
Number of subjects: 137
Study: 26168672

Group type: EXPERIMENTAL
Intervention: Conjoined tendon reconstruction group (n = 36)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tractusiliotibialis reconstruction group (n = 38)
Number of subjects: 74
Study: 23943217

Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 39

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 39
Study: 21388444

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Parasympathetic dysfunction
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: E/I ratio correlations
Number of subjects: 268
Study: 18347350

Group type: EXPERIMENTAL
Intervention: High-risk adenomas (defined as > or =3 adenomas or any advanced adenomas)
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Low-risk adenomas (defined as 2 or fewer nonadvanced adenomas)
Number of subjects: 1905

Group type: COMPARATOR
Intervention: High-risk adenomas
Number of subjects: 1905
Study: 16969592

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg administered intravenously every 3 months
Number of subjects: 23
Study: 12954157

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 10
Study: 12212156

Group type: EXPERIMENTAL
Intervention: PN with lower energy (105 KJ.kg‐1.d‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PN with higher energy (146 KJ.kg‐1.d‐1)
Number of subjects: 30
Study: 8818849

Group type: EXPERIMENTAL
Intervention: 500 mg azithromycin, administered orally once daily for 3 days
Number of subjects: 440

Group type: COMPARATOR
Intervention: 150 mg roxithromycin, given orally twice daily for 10 days
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: azithromycin
Number of subjects: 440

Group type: COMPARATOR
Intervention: roxithromycin
Number of subjects: 440
Study: 7819707

Group type: EXPERIMENTAL
Intervention: buserelin-long
Number of subjects: 0

Group type: COMPARATOR
Intervention: buserelin-short
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: leuprolide-long
Number of subjects: 0

Group type: COMPARATOR
Intervention: leuprolide-short
Number of subjects: 0
Study: 3052116

Group type: EXPERIMENTAL
Intervention: Nurse home visitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison services
Number of subjects: 0
Study: 30118904

Group type: EXPERIMENTAL
Intervention: Hybrid light activation (HL) with prior enamel acid etching (37% phosphoric acid for 15s) and 35% hydrogen peroxide gel (HP) applied for 3-4 consecutive applications with 2×3' activations (1' interval)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hybrid light activation (HL) without prior enamel acid etching and 35% hydrogen peroxide gel (HP) applied for 3-4 consecutive applications with 2×3' activations (1' interval)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (GIII and IV) without HL, receiving 35% hydrogen peroxide gel (HP) applied for 3×15' without HL
Number of subjects: 34
Study: 25682724

Group type: EXPERIMENTAL
Intervention: Duct to mucosa pancreaticojejunostomy (G1)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Invagination pancreaticojejunostomy (G2)
Number of subjects: 107
Study: 23726721

Group type: EXPERIMENTAL
Intervention: Always abstinent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluctuating use, abuse, and occasional abstinence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occasional (ab)use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stopped (ab)use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abusing
Number of subjects: 0
Study: 20846200

Group type: EXPERIMENTAL
Intervention: LEC group - levofloxacin 500 mg, esomeprazole 40 mg, clarithromycin 500 mg once daily for 7 days
Number of subjects: 189

Group type: COMPARATOR
Intervention: AEC group - amoxicillin 1 g, esomeprazole 40 mg, clarithromycin 500 mg twice daily for 7 days
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 189
Study: 18223614

Group type: EXPERIMENTAL
Intervention: 26% dietary fat treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 34% dietary fat treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 40% dietary fat treatment
Number of subjects: 22
Study: 16565237

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 to 80 mg)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Enalapril (10 to 20 mg)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Telmisartan and Enalapril
Number of subjects: 250
Study: 14578725

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10937427

Group type: EXPERIMENTAL
Intervention: Cough induced with inhaled citric acid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (estimation of lemon flavors)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thresholds for citric acid (50% of thresholds)
Number of subjects: 30
Study: 9017582

Group type: EXPERIMENTAL
Intervention: Cisplatin or carboplatin containing chemotherapy
Number of subjects: 1052
Study: 1460118

Group type: EXPERIMENTAL
Intervention: Isotretinoin cream, applied once nightly for 36 weeks
Number of subjects: 776

Group type: COMPARATOR
Intervention: Vehicle cream, applied once nightly for 36 weeks
Number of subjects: 776
Study: 6381871

Group type: EXPERIMENTAL
Intervention: Human insulin (0.075 IU/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Porcine insulin (0.075 IU/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human insulin (0.12 IU/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Porcine insulin (0.12 IU/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human insulin and Porcine insulin
Number of subjects: 0
Study: 31113795

Group type: EXPERIMENTAL
Intervention: AZD5069
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD4721
Number of subjects: 0
Study: 30829265

Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT)
Number of subjects: 64
Study: 26875824

Group type: EXPERIMENTAL
Intervention: Bendamustine-Rituximab (BR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP/R-CVP (standard therapy)
Number of subjects: 0
Study: 25382402

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000 IU 3×/week)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 19
Study: 22350925

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PR-M) 2 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zolpidem 10 mg (active control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20827170

Group type: EXPERIMENTAL
Intervention: Uridine (NucleomaxX)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 17577041

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 9970

Group type: COMPARATOR
Intervention: FU-based combination chemotherapy
Number of subjects: 9970

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 9970

Group type: EXPERIMENTAL
Intervention: Gemcitabine combination chemotherapy
Number of subjects: 9970
Study: 16030464

Group type: EXPERIMENTAL
Intervention: Computer-based system for continence health promotion (n = 36)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait list control group using an alternate system (n = 35)
Number of subjects: 71
Study: 12042621

Group type: EXPERIMENTAL
Intervention: Direct stenting without predilatation (group I)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Stenting with predilatation (group II)
Number of subjects: 145
Study: 10450005

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no NP)
Number of subjects: 26
Study: 7781622

Group type: EXPERIMENTAL
Intervention: Iatrogenic hypercortisolemia treatment for underlying diseases in pregnant women
Number of subjects: 0
Study: 2403833

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 219

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 219
Study: 363335

Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate
Number of subjects: 12
Study: 31785550

Group type: EXPERIMENTAL
Intervention: Racially concordant/discordant video-based decision support tool
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Racially concordant video
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Racially discordant video
Number of subjects: 350
Study: 30694917

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg daily
Number of subjects: 631

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study: 28658165

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy (invasive procedures such as endoscopic injection sclerotherapy or endoscopic band ligation) for esophageal varices
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Increased SMI group (n=15)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: BTR as a prognostic factor
Number of subjects: 51
Study: 26119895

Group type: EXPERIMENTAL
Intervention: mini-open TLIF
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: corrective TLIF
Number of subjects: 3

Group type: COMPARATOR
Intervention: corrective TLIF with instrumentation-related complications
Number of subjects: 3
Study: 24013130

Group type: EXPERIMENTAL
Intervention: rtfMRI training sessions to up-regulate DLPFC activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rtfMRI training sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (sham feedback)
Number of subjects: 0
Study: 20861416

Group type: EXPERIMENTAL
Intervention: Nitrous oxide-based anesthesia
Number of subjects: 2050

Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthesia
Number of subjects: 2050
Study: 19223606

Group type: EXPERIMENTAL
Intervention: Psychosocial group rehabilitation intervention
Number of subjects: 235
Study: 16687711

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (88 mcg twice daily)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Masked placebo
Number of subjects: 285
Study: 14704799

Group type: EXPERIMENTAL
Intervention: Convergent dynamic random-dot stereograms (DRDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divergent dynamic random-dot stereograms (DRDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Convergent DRDS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divergent DRDS
Number of subjects: 0
Study: 11742776

Group type: EXPERIMENTAL
Intervention: Use of external hip protectors and encouragement by nurses to use the protectors
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (no hip protectors)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Use of external hip protectors
Number of subjects: 174
Study: 9431483

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8219947

Group type: EXPERIMENTAL
Intervention: Senna-fibre combination (10 ml daily)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Lactulose (15 ml twice daily)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Senna-fibre combination
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 77
Study: 3676920

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-Dopa (Sinemet)
Number of subjects: 0
Study: 29282600

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75 mg/m2 for 60 min at 43 °C
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 33
Study: 27092908

Group type: EXPERIMENTAL
Intervention: Modified Millard repair with alar base incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal wide dissection
Number of subjects: 0
Study: 25047090

Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/day)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 22247489

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Vision-related function score (NEI VFQ-25)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Visual function score
Number of subjects: 255
Study: 20520601

Group type: EXPERIMENTAL
Intervention: 100 mg caffeine followed by 150 mg caffeine 90 min later
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg and 150 mg)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Caffeine (frequent consumption)
Number of subjects: 379
Study: 18937268

Group type: EXPERIMENTAL
Intervention: Appearance-focused intervention (booklet based on decision-theoretical models of health behavior)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Appearance-focused intervention
Number of subjects: 430
Study: 17003661

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 12704369

Group type: EXPERIMENTAL
Intervention: Long synthetic overlapping peptides (LSP) immunotherapy, 100 microg per peptide, injected at days 0, 4, 7, 14, 42, and 70.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group injected with human albumin.
Number of subjects: 0
Study: 10890620

Group type: EXPERIMENTAL
Intervention: NIMV with a nasal mask
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NIMV with a full‐face mask
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NIMV with nasal plugs
Number of subjects: 26

Group type: COMPARATOR
Intervention: NIMV with assist control or pressure‐assisted modes
Number of subjects: 26
Study: 8956953

Group type: EXPERIMENTAL
Intervention: Blood samples collected from patients with multiple injuries
Number of subjects: 40
Study: 1347267

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clemastine 2 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3160266

Group type: EXPERIMENTAL
Intervention: HealthScan Assess peak flow meter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Wright Peak Flow Meter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HealthScan Assess peak flow meters (six units)
Number of subjects: 0
Study: 31496423

Group type: EXPERIMENTAL
Intervention: Community empowerment-based model of combination HIV prevention
Number of subjects: 0
Study: 27171538

Group type: EXPERIMENTAL
Intervention: Adapted physical activity-based rehabilitation (N=304)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 321
Study: 27023447

Group type: EXPERIMENTAL
Intervention: TSH ≥ 2.5 mIU/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyroid autoimmunity
Number of subjects: 0

Group type: COMPARATOR
Intervention: TSH < 2.5 mIU/L
Number of subjects: 0
Study: 23873889

Group type: EXPERIMENTAL
Intervention: 3D roadmap technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2D roadmap technique
Number of subjects: 40
Study: 22410350

Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 176
Study: 20463178

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 microg
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg
Number of subjects: 1683

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1683
Study: 18360012

Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Telmisartan (40 mg/day)
Number of subjects: 20
Study: 16102606

Group type: EXPERIMENTAL
Intervention: Routine EUS-FNA
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional workup (CWU)
Number of subjects: 104
Study: 12059931

Group type: EXPERIMENTAL
Intervention: Fermin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Caviton
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cavit
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Canseal (two groups tested)
Number of subjects: 160
Study: 10078667

Group type: EXPERIMENTAL
Intervention: Clonidine (6 microg/kg orally 120 min before anesthesia and 3 microg/kg intravenously over 60 min before the end of surgery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 20
Study: 7724385

Group type: EXPERIMENTAL
Intervention: Epicardial patch (EPI)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nonthoracotomy CPI Endotak (ENDO)
Number of subjects: 67